Deliver a clot even when your patient can’t

VISTASEAL™ Fibrin Sealant (Human) mimics the clot formation process and forms a rapid, adherent, and durable clot regardless of the patient’s coagulation profile.²⁻¹²

No other fibrin sealant preps faster³

- **Pre-filled syringes** with click-on dual applicator, all in one box
- **No CO₂ needed**—Airless Spray Technology eliminates the need for external spraying equipment
- Once thawed, **no additional warming needed** vs TISSEEL (4 minutes to warm)²⁻¹⁴

Designed for performance

- **Flexibility** to drip or spray—narrow to broad
- **Malleable tip** provides precise application to challenging anatomy
- **Broader range of working temperature for clinical use (2°C to 37°C)** vs TISSEEL (33°C to 37°C)²⁻¹⁴

Potential Rebleeding Risk Situation

Bleeding may be addressed intraoperatively but could later develop into more serious complications, especially in high-risk patients.

VISTASEAL

Part of the Hemostasis Optimization Program—a systematic approach to bleeding management

*Based on number of set-up steps and thawing time required for VISTASEAL™ Dual Applicator vs competition

*Refers to 10 mL TISSEEL device
VISTASEAL™ Fibrin Sealant (Human) IMPORTANT SAFETY INFORMATION

INDICATION
VISTASEAL™ is indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. VISTASEAL is effective in heparinized patients.

CONTRAINDICATIONS
Do not inject directly into the circulatory system.
Do not use for the treatment of severe or brisk arterial bleeding.
Do not use in patients with history of anaphylaxis or severe systemic reactions to human blood products.
Do not use VISTASEAL for spraying unless the minimum recommended distance from the applicator tip to the bleeding site can be achieved.

WARNINGS AND PRECAUTIONS
Thromboembolic events may occur if VISTASEAL is administered intravascularly.
Only spray VISTASEAL if it is possible to accurately judge the distance from the spray tip to the tissue surface.
Hypersensitivity reactions can occur.
May carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

ADVERSE REACTIONS
The most common adverse reactions (reported in >1% of clinical trial subjects) were nausea and procedural pain.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.


Ordering Information

VST02: 1 x 2 mL Device
VST04: 1 x 4 mL Device
VST10: 1 x 10 mL Device
VSTL35: 3 x 35 cm Lap (Rigid)
VSTL45: 3 x 45 cm Lap (Flex)
04VST10: 4 x 10 mL Devices
12VST10: 12 x 10 mL Devices

Go green by ordering kits!